ZURICH/BERLIN, Dec 20(Reuters) - Here are some of the
main factors that may affect Swiss stocks on Tuesday:
IDORSIA
Swiss biotech company Idorsia has submitted a new
application for approval of the drug aprocitentan to the U.S.
Food and Drug Administration. urn:newsml:reuters.com:*:nTUA303TRV
COMPANY STATEMENT
* Sika SIKA.S said it is opening a new plant for liquid
membranes and mortar production in Southwestern China. SIKA.S
* Perestroika (Cyprus) Ltd reported a 11.4% stake in
Transocean Ltd RIGN.S as of Dec. 12, 2022 versus 9.94% as of
May 13, 2022, according to an SEC filing. RIGN.S
* SIG Group SIGNC.S announced the departure of CFO Frank
Herzog on Tuesday. SIGNC.S
ANALYSTS' VIEWS
KARDEX HOLDING AG KARN.S : JEFFERIES CUTS TARGET PRICE TO
CHF 200 FROM CHF 205
CREDIT SUISSE GROUP AG CSGN.S : RBC REINSTATES COVERAGE
WITH SECTOR PERFORM RATING; TARGET PRICE CHF 3.50
CREDIT SUISSE GROUP AG CSGN.S: CITIGROUP RESUMES COVERAGE
WITH BUY RATING; TARGET PRICE CHF 3.7
ECONOMY
Swiss November trade balance due at 0700 GMT.
(Reporting by Zurich newsroom and Berlin Speed Desk)
((+41 58 306 7336; zurich.newsroom@thomsonreuters.com))
((For Top News in a multimedia Web format on Eikon visit: https://bit.ly/2NDFd6g
FOR RELATED PRICES, NEWS AND OTHER TOPICS, DOUBLE-CLICK ON:
Daily Swiss stock market report in German .SDE
All SMI constituent stocks 0#.SSMI
DJ STOXX index .STOXX
Top 10 STOXX sectors .PGL.STOXXS
Top 10 EUROSTOXX sectors .PGL.STOXXES
Swiss mid-cap index .SSMI
Swiss all-share index .SSHI
Swiss market digest .AD.S
Sector overview CH/SECTOR1
All Swiss news CH
Swiss research news CH-RCH
All equity news E
SPEED GUIDES: EQUITY EQUITY/NEWS1 EUR/EQUITY SWITZERLAND REUTERS ))